This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
Author: Avi Kapoor | May 08, 2025 10:42am
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Chardan Capital analyst Rudy Li initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a Buy rating and announced a price target of $30. Centessa Pharmaceuticals shares closed at $12.11 on Wednesday. See how other analysts view this stock.
Oppenheimer analyst Andreas Argyrides initiated coverage on InflaRx N.V. (NASDAQ:IFRX) with an Outperform rating and announced a price target of $6. InflaRx shares closed at $1.49 on Wednesday. See how other analysts view this stock.
Considering buying CNTA stock? Here’s what analysts think:
